Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers

Contraception

Volumn 58, Issue 1, 1998, Pages 39-44

  Mulders, T M T ^a   Mink, C P A ^b   Bobbink, I W G ^b   Bennink, H J T Coelingh ^a  

^a Clinical Development Department   (Netherlands)

^b Dept of Drug Metab and Kinetics ^*  (Netherlands)

Author keywords

Antiprogestagens; Human pharmacokinetics; Org 31710; Safety

Indexed keywords

11 (4 DIMETHYLAMINOPHENYL) 6 METHYL 4',5' DIHYDROSPIRO[ESTRA 4,9 DIENE 17,2'(3H) FURAN] 3 ONE; 11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; 19 NORSTEROID; ALDOSTERONE; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FLUOROIMMUNOASSAY; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION;

BIOLOGY; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTION RESEARCH; DEVELOPED COUNTRIES; ENDOCRINE SYSTEM; EUROPE; FAMILY PLANNING; HORMONE ANTAGONISTS--ADMINISTRACTION AND DOSAGE; HORMONE ANTAGONISTS--PHARMACODYNAMICS; HORMONES; MALE CONTRACEPTION; NETHERLANDS; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; WESTERN EUROPE;

ADOLESCENT; ADULT; ESTRENES; FOLLICLE STIMULATING HORMONE; FURANS; HALF-LIFE; HORMONE ANTAGONISTS; HUMANS; KINETICS; LUTEINIZING HORMONE; MALE; PROGESTINS; TESTOSTERONE;

EID: 0032124457     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(98)00053-5     Document Type: Article

References (20)

1. Hodgen G.D. Antiprogestins the political chemistry of RU486 (editorial) . Fertil Steril. 56:1991;394-395.
2. Liu J.H., Garzo G., Morris S., Stuenkel C., Ulmann A., Yen S.S.C. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. J Clin Endocrinol Metab. 65:1987;1135-1140.
3. Shoupe D., Mishell D.R. Jr, Page M.A., Madkour H., Spitz I.M., Lobo R.A. Effects of the antiprogesterone RU486 in normal women. II. Administration in the late follicular phase. Am J Obstet Gynecol. 157:1987;1421-1426.
4. Luukkainen T., Heikinheimo O., Haukkamaa M., Lähteenmäki P. Inhibition of folliculogenesis and ovulation by the anti-progesterone RU486. Fertil Steril. 49:1988;961-963.
5. Croxatto H.B., Salvatierra A.M., Fuentealba B., Zurth C., Beier S. Effect of onapristone on follicular growth in women. Hum Reprod. 9:1994;1442-1447.
6. Batista M.C., Cartledge T.P., Zellmer A.W., et al. Delayed endometrial maturation induced by daily administration of the anti-progestin RU486 a potential new contraceptive strategy . Am J Obstet Gynecol. 167:1992;60-65.
7. Greene K.E., Kettle L.M., Yen S.S.C. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of the luteal phase of the menstrual cycle a contraceptive potential . Fertil Steril. 58:1992;338-343.
8. Glasier A., Thong K.J., Dewar M., Mackie M., Baird D.T. Mifepristone (RU486) compared with high-dose estrogen and progestagen for emergency postcoital contraception. N Engl J Med. 327:1992;1041-1044.
9. Webb A.M.C., Russell J., Elstein M. Comparison of Yuzpe regimen, danazol and mifepristone (RU486) in oral postcoital contraception. Br Med J. 305:1992;927-931.
10. Bakker G.H., Setyono-Han B., Portengen H., De Jong F.H., Foekens J.A., Klijn J.G.M. Treatment of breast cancer with different anti-progestins preclinical and clinical studies . J Steroid Biochem Mol Biol. 37:1990;789-794.
11. Brogden R.N., Goa K.L., Faulds D. Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 45:1993;384-409.
12. Kloosterboer H.J., Deckers G.H.J., Van der Heuvel M.J., Loozen H.J.J. Screening of anti-progestagens by receptor studies and bioassays. J Steroid Biochem. 31:1988;567-571.
13. Kloosterboer H.J., Deckers G.H., Schoonen W.G.E.J. Pharmacology of two new very selective anti-progestagens Org 31710 and Org 31806 . Hum Reprod. 9:1994;47-52.
14. Deraedt R., Bonnat C., Busigny M., et al. Pharmacokinetics of RU486. Baulieu E.E., Segal S.J. The Antiprogestin Steroid RU486 and Human Fertility Control. 1985;103-122 Plenum Press, New York.
15. Lähteenmäki P., Heikinheimo O., Croxatto H., et al. Pharmacokinetics and metabolism of RU486. J Steroid Biochem. 27:1987;859-863.
16. Heikinheimo O., Tevilin M., Shoupe D., Croxatto H., Lähteenmäki P. Quantitation of RU486 in human plasma by HPLC and RIA after column chromatography. Contraception. 34:1986;613-624.
17. Heikinheimo O., Lähteenmäki P.L.A., Koivunen E., et al. Metabolism and serum binding of RU 486 in women after various single doses. Hum Reprod. 2:1987;379-385.
18. Shi Y., Ye Z., He C., et al. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception. 48:1993;133-149.
19. Kekkonen R., Heikinheimo O., Mandelin E., Lähteenmäki P. Pharmacokinetics of mifepristone after low oral doses. Contraception. 54:1996;229-234.
20. Heikinheimo O. Pharmacokinetics of the anti-progesterone RU486 in women during multiple dose administration. J Steroid Biochem. 32:1989;21-25.